Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.

International journal of cancer - 15 Dec 2015

Toffoli Giuseppe, Giodini Luciana, Buonadonna Angela, Berretta Massimiliano, De Paoli Antonino, Scalone Simona, Miolo Gianmaria, Mini Enrico, Nobili Stefania, Lonardi Sara, Pella Nicoletta, Lo Re Giovanni, Montico Marcella, Roncato Rossana, Dreussi Eva, Gagno Sara, Cecchin Erika

Abstract excerpt

Pre-therapeutic DPYD pharmacogenetic test to prevent fluoropyrimidines (FL)-related toxicities is not yet common practice in medical oncology. We aimed at investigating the clinical validity of DPYD genetic analysis in a large series of oncological patients. Six hundred three cancer patients, treated with FL, have been retrospectively tested for eight DPYD polymorphisms (DPYD-rs3918290, DPYD-rs55886062,...

Read the complete abstract on PubMed

Topics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over
Share to Antimetabolites, Antineoplastic
Share to Dihydrouracil Dehydrogenase (NADP)
Share to Fluorouracil
Share to Genetic Testing
Share to Neoplasms
Share to Young Adult

Source

Identifiers

PMID: 26099996
DOI: 10.1002/ijc.29654

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.PMID 26099996Read ↗

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read ↗

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in GreeceSemantic proximity Read ↗

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.Semantic proximity Read ↗

Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.Semantic proximity Read ↗

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.Semantic proximity Read ↗

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.Semantic proximity Read ↗

Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.Semantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control studySemantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.